Kim Clark-Langone

Kim has spent over 20 years leading multi-disciplinary teams focused on biomarker discovery and the development of molecular diagnostics. Kim comes to CareDx from Talis Biomedical Corp., where she was Senior Director, Assay Development. Prior to Talis, Kim spent 19 years at Genomic Health Inc./Exact Sciences Corp., where she held various roles of increasing responsibility, including Senior Director, Assay and Informatics Development. There, she was involved in the development and validation of a suite of OncotypeDX® gene expression tests for breast, colon and prostate cancer and led the development and validation of a liquid biopsy mutation panel, Oncotype SEQ™ Liquid Select. Recently at CareDx, Kim has led assay improvements for AlloSure®️ and the development of XenoSure™, a donor-derived cell-free DNA (dd-cfDNA) assay for xenotransplant recipients. Kim received her BSc in genetics and her Ph.D. in mitochondrial genetics at the University of Newcastle upon Tyne, England, and completed her post-doctoral studies on the role of mitochondrial DNA dimers in cancer at Stanford University.